Literature DB >> 17515853

Absence of functional peroxisome proliferator-activated receptor-alpha enhanced ileum permeability during experimental colitis.

Emanuela Mazzon1, Salvatore Cuzzocrea.   

Abstract

The aim of the present study was to examine the role of endogenous peroxisome proliferator-activated receptor-alpha (PPAR-alpha) ligand on the permeability and structure of small intestine tight junctions (TJs) in an animal model of experimental colitis, induced by dinitrobenzene sulfuric acid (DNBS). Four days after colitis induction with DNBS, the ileal TJs were studied by means of transmission electron microscopy using lanthanum nitrate and immunohistochemistry of occludin, zonula occludens 1, and claudin 2. Administration of DNBS to wild-type mice induced colon injury associated with a significant increase of plasma and colon tumor necrosis factor-alpha levels and with a significant increase of ileal permeability. Distal colitis in mice induced an increase of TJ permeability throughout the entire small intestine, and the extent of alterations correlates with colonic damage. Small intestinal permeability was associated with the presence of apoptosis (evaluated by FAS ligand expression and terminal deoxynucleotidyltransferase-mediated UTP nick end labeling coloration), which was associated with a significantly increased expression of proapoptotic Bax and decreased ileum content of antiapoptotic Bcl-2. Absence of a functional PPAR-alpha gene in PPAR-alpha knockout mice resulted in a significant augmentation of all the above-described parameters. Taken together, our results clearly demonstrate that endogenous PPAR-alpha ligands reduced small intestinal permeability in experimental colitis through the regulation of apoptosis and TJ protein.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17515853     DOI: 10.1097/SHK.0b013e318033eb29

Source DB:  PubMed          Journal:  Shock        ISSN: 1073-2322            Impact factor:   3.454


  13 in total

1.  Claudin-2 as a mediator of leaky gut barrier during intestinal inflammation.

Authors:  J Luettig; R Rosenthal; C Barmeyer; J D Schulzke
Journal:  Tissue Barriers       Date:  2015-04-03

Review 2.  Claudins and the modulation of tight junction permeability.

Authors:  Dorothee Günzel; Alan S L Yu
Journal:  Physiol Rev       Date:  2013-04       Impact factor: 37.312

3.  Changes in the phosphorylation of claudins during the course of experimental colitis.

Authors:  Jing Li; Yong-Xiang Li; Mei-Hua Chen; Jie Li; Juan Du; Bing Shen; Xian-Ming Xia
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

4.  CXCR4 antagonist AMD3100 attenuates colonic damage in mice with experimental colitis.

Authors:  Xian-Ming Xia; Fang-Yu Wang; Wen-An Xu; Zhen-Kai Wang; Jiong Liu; You-Ke Lu; Xin-Xin Jin; Heng Lu; Yun-Zhu Shen
Journal:  World J Gastroenterol       Date:  2010-06-21       Impact factor: 5.742

5.  Targeting the gut barrier: identification of a homing peptide sequence for delivery into the injured intestinal epithelial cell.

Authors:  Todd W Costantini; James G Putnam; Ritsuko Sawada; Andrew Baird; William H Loomis; Brian P Eliceiri; Vishal Bansal; Raul Coimbra
Journal:  Surgery       Date:  2009-08       Impact factor: 3.982

6.  PPAR-gamma agonist protects against intestinal injury during necrotizing enterocolitis.

Authors:  Naira Baregamian; Joshua M Mourot; Amie R Ballard; B Mark Evers; Dai H Chung
Journal:  Biochem Biophys Res Commun       Date:  2008-12-27       Impact factor: 3.575

7.  Effects of verbascoside biotechnologically produced by Syringa vulgaris plant cell cultures in a rodent model of colitis.

Authors:  Emanuela Mazzon; Emanuela Esposito; Rosanna Di Paola; Luisa Riccardi; Rocco Caminiti; Roberto Dal Toso; Giovanna Pressi; Salvatore Cuzzocrea
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-02-26       Impact factor: 3.000

8.  Ulcerative colitis impairs the acylethanolamide-based anti-inflammatory system reversal by 5-aminosalicylic acid and glucocorticoids.

Authors:  Juan Suárez; Yanina Romero-Zerbo; Lucia Márquez; Patricia Rivera; Mar Iglesias; Francisco J Bermúdez-Silva; Montserrat Andreu; Fernando Rodríguez de Fonseca
Journal:  PLoS One       Date:  2012-05-25       Impact factor: 3.240

9.  CXCR4 antagonist AMD3100 modulates claudin expression and intestinal barrier function in experimental colitis.

Authors:  Xian-Ming Xia; Fang-Yu Wang; Ju Zhou; Kai-Feng Hu; Su-Wen Li; Bing-Bing Zou
Journal:  PLoS One       Date:  2011-11-03       Impact factor: 3.240

10.  PPARs Mediate Lipid Signaling in Inflammation and Cancer.

Authors:  Liliane Michalik; Walter Wahli
Journal:  PPAR Res       Date:  2008-12-21       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.